Usage and dosage of tremelimumab/tremelimumab combined with durvalumab

Tremelimumab/Tremelimumab contains tremelimumab at a concentration of 20 mg/ml in 25 mg/1.25 ml or 300 mg/1 Imjudo is available in 5 ml single-dose vials as 1.25 ml 25 mg and 15 ml 300 mg disposable vials (both 20 mg/ml).

Both drugs, temsitumumab and durvalumab, are administered intravenously, and recommended dosage regimens vary by indication and body weight. For adults weighing more than 30 kg, the recommended dose of tremelimumab is 300 mg and the recommended dose of durvalumab is 1500 mg. For hepatocellular carcinoma, give a single initial dose of tremelimumab followed by durvalumab every 4 weeks until disease progression or unacceptable toxicity. For non-small cell lung cancer, the combination of tremelimumab 75 mg and durvalumab 1500 mg is administered every 3 weeks for 4 cycles, followed by durvalumab every 4 weeks. Side effects of this combination are common and include rash, diarrhea, abdominal pain, nausea, vomiting, itching, and fatigue.

Tremelimumab/Tremelimumab is a new type of cancer immunotherapy drug. It has not yet been launched in China, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. It is understood that the US version of temsitumumab original drug sold overseas may cost more than more than 3,000 US dollars per box, and the specification is 300mg/50mL (20mg/mL). The price is still relatively expensive. At present, we are not aware of the production and release of generic drugs of temsitumumab. For specific overseas prices and drug details, please consult Yaode Medical Consultants.